These days, many of the most frequently asked questions that we receive focus on GLP-1 medications––the popular and highly effective weight loss drugsyou’ve been hearing about in the news.GLP-1s are a type of incretin mimetic, medications that affect gut hormones and cause w...
肥胖治疗理念正在从治疗肥胖相关疾病兼顾体重管理逐步向针对肥胖本身的药物(anti-obesity medications, AOMs)转变。其中,以胰高糖素样肽-1受体(GLP-1R)、葡萄糖依赖性促胰岛素多肽受体(GIPR)和胰高糖素受体(GCGR)为主要靶点的AOM取得了一系列的...
肥胖治疗理念正在从治疗肥胖相关疾病兼顾体重管理逐步向针对肥胖本身的药物(anti-obesity medications, AOMs)转变。其中,以胰高糖素样肽-1受体(GLP-1R)、葡萄糖依赖性促胰岛素多肽受体(GIPR)和胰高糖素受体(GCGR)为主要靶点的AOM取得了一系列的研究成果(表1),并部分被美国食品药品监督管理局(FDA)批准用于肥胖症的...
Lately, the class of mineralocorticoid receptor antagonist drugs has been enriched by finerenone. This molecule has favourable pharmacokinetic characteristics compared with previous medications of the same class and tested in Phase 3, randomized, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD) ...
both on its own and after the consumption of a mixed-nutrient drink in healthy men. However, the contribution of GLP-1 to insulin stimulation was likely modest, and further evaluation using a GLP-1 receptor antagonist would be necessary. Additionally, studies in patients with T2DM are now need...
In fact, the peptide acts as a weak GLP-1R antagonist, clearly counteracting the biological effects of GLP-1 (7-36amide) in vitro [204]. 6. Regulation of GLP-1 secretion 6.1. Intestinal distribution of the L-cells Although there is some species variation, the density of L-cells is ...
13 Thus, data in nondiabetic CKD are coming, but dedicated outcome studies are still lacking, and we will need studies to compare the available medications for this group as well. Another treatment option for patients with diabetic CKD is the nonsteroidal mineralocorticoid receptor antagonist fine...
Individuals were included if they had initiated one or more of the following four second- line glucose-lowering medications: SGLT2is, GLP1-RAs, dipeptidyl peptidase-4 inhibitors (DPP4is) or sulfonylureas (SUs). Treatment initiation was defined as a filled prescrip- tion for a study medication ...
both on its own and after the consumption of a mixed-nutrient drink in healthy men. However, the contribution of GLP-1 to insulin stimulation was likely modest, and further evaluation using a GLP-1 receptor antagonist would be necessary. Additionally, studies in patients with T2DM are now need...
Pat. No. 6,864,069 as acting as both a GLP-1 agonist and a glucagon antagonist for treating diabetes are also excluded as glucagon/GLP-1 co-agonist molecules. In another embodiment, excluded is the use of glucagon antagonists to treat diabetes, such as the antagonists described in Unson ...